Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Simrat Randhawa sold 33,830 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Dianthus Therapeutics Price Performance

Shares of DNTH stock traded down $2.46 during midday trading on Friday, reaching $77.86. 2,278,752 shares of the company traded hands, compared to its average volume of 1,180,013. The firm’s 50 day simple moving average is $52.53 and its two-hundred day simple moving average is $42.56. The firm has a market cap of $3.46 billion, a PE ratio of -18.99 and a beta of 1.56. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $88.02.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The firm had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on DNTH shares. Stifel Nicolaus set a $120.00 price objective on shares of Dianthus Therapeutics in a research note on Monday. Robert W. Baird raised their price target on Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday. Jefferies Financial Group set a $98.00 price objective on Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Finally, Raymond James Financial raised shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $63.00 to $123.00 in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $115.33.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNTH. Fairmount Funds Management LLC raised its holdings in Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after acquiring an additional 600,000 shares during the last quarter. Vestal Point Capital LP boosted its holdings in shares of Dianthus Therapeutics by 88.2% during the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after purchasing an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after purchasing an additional 2,503,311 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Dianthus Therapeutics by 24.7% in the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the period. Finally, TCG Crossover Management LLC grew its position in shares of Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after purchasing an additional 175,000 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.